Other GLP-1 Agonists : Combining Zepbound with other GLP-1 receptor agonists (Semaglutide, Liraglutide, or Dulaglutide) is generally not advised due to similar mechanisms of action and an increased risk of side effects.
Before halting coverage, the SHP was projected to spend $170 million on weight loss drugs in 2024
The Triple-Agonist Mechanism Energy Expenditure: Studied via glucagon receptor pathways Insulin Secretion: GLP-1 and GIP mediated signaling Lipid Metabolism: Adipose tissue and hepatic fat models For a mechanistic comparison, see: Retatrutide vs Tirzepatide Research Comparison
38.6% achieved 15% weight loss
The best outcome is getting the diagnosis right metabolic, airway, jaw, joint and building a plan that handles each part on its own terms
However, this fear is based on a misunderstanding of how these medications function